We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.58 | 6.17% | 27.20 | 27.45 | 26.02 | 26.3295 | 97,520,313 | 00:58:40 |
From May 2019 to May 2024
By Colin Kellaher
Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration approved Abrilada, its biosimilar to AbbVie Inc.'s (ABBV) blockbuster Humira, for multiple inflammatory conditions.
The New York drug maker said the approval covers the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.
Pfizer said it currently plans to launch Abrilada in the U.S. in 2023 based on the terms of its 2018 licensing agreement with AbbVie.
Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells and are analogous to generic copies of traditional pill-form medicines.
Humira, used to treat diseases from rheumatoid arthritis to gut disorders, is the world's biggest-selling drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 18, 2019 07:14 ET (12:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
